16194-64-2

Upstream product

• 1544-68-9 4-fluorophenyl isothiocyanate 
• 21258-13-9 N-(4-Fluor-phenyl)-N'-acetyl-thioharnstoff 
• 371-40-4 4-fluoroaniline 
• 459-05-2 (4-fluoro-phenyl)-thiourea 
• 348-40-3 2-amino-6-fluoro-1,3-benzothiazole 
• 108-24-7 acetic anhydride 

Relevant academic research and scientific papers

Neurodegenerative Therapies

The present invention provides a compound of formula (I) wherein: Y represents a C or N atom which may be substituted or form a cyclic group with R′″ but may not be a quaternary C atom; R′ is —OR1, —CONH2, —CF3, F, —OH, —NO2, —CN or —OCOR1 in which R1, is C1-3 alkyl and each may be in the beta or gamma position; R″ is C1-3 alkyl or H; and R′″ is H or a group consisting of 1-12 non-hydrogen atoms and may be linear, branched and/or incorporate one or more cyclic groups, cyclic groups may be aromatic and/or heterocyclic and 2 or more cyclic groups may be linked or fused and each may be substituted; or a salt, hydrate or solvate of a compound of formula (I) for use in the treatment or prevention of a neurodegenerative disorder by inhibiting formation of neurofibrillary (tau) tangles and/or by inhibiting Dyrk 1A. The invention further relates to non-therapeutic uses of these compounds.

Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules

DYRK1A has emerged as a potential target for therapies of Alzheimer's disease using small molecules. On the basis of the observation of selective DYRK1A inhibition by firefly d-luciferin, we have explored static and dynamic structural properties of fragment sized variants of the benzothiazole scaffold with respect to DYRK1A using X-ray crystallography and NMR techniques. The compounds have excellent ligand efficiencies and show a remarkable diversity of binding modes in dynamic equilibrium. Binding geometries are determined in part by interactions often considered "weak", including "orthogonal multipolar" types represented by, for example, F-CO, sulfur-aromatic, and halogen-aromatic interactions, together with hydrogen bonds that are modulated by variation of electron withdrawing groups. These studies show how the benzothiazole scaffold is highly promising for the development of therapeutic DYRK1A inhibitors. In addition, the subtleties of the binding interactions, including dynamics, show how full structural studies are required to fully interpret the essential physical determinants of binding.

Synthesis of N-benzothiazol-2-yl-amides by Pd-catalyzed C(sp2)-H functionalization

A catalytic synthesis of N-benzothiazol-2-yl-amides from 1-acyl-3-(phenyl)thioureas was achieved in the presence of a palladium catalyst through the C(sp2)-H functionalization/C-S bond formation. This synthetic methodology can produce various N

Synthesis of N-benzothiazol-2-yl-amides by an iron-catalyzed oxidative C(sp2)-H functionalization

Catalytic synthesis of N-benzothiazol-2-yl-amides from 1-acyl-3-(phenyl) thioureas was achieved in the presence of an iron catalyst through C(sp 2)-H functionalization and C-S bond formation. Various N-benzothiazol-2-yl-amides were selectively obtained in good yields. Georg Thieme Verlag Stuttgart, New York.